# Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases

> **NCT01802645** · PHASE2 · UNKNOWN · sponsor: **Technische Universität Dresden** · enrollment: 91 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Bevacizumab
- **DRUG:** Irinotecan
- **DRUG:** Oxaliplatin
- **DRUG:** 5-FU
- **DRUG:** Folinic Acid

## Key facts

- **NCT ID:** NCT01802645
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03
- **Primary completion:** 2019-09
- **Final completion:** 2020-12
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2019-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01802645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01802645, "Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01802645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*